Compare IPGP & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | SRRK |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 6.6B |
| IPO Year | 2000 | 2018 |
| Metric | IPGP | SRRK |
|---|---|---|
| Price | $105.37 | $54.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $131.40 | $56.17 |
| AVG Volume (30 Days) | 364.1K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 117.85 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $1,003,777,000.00 | N/A |
| Revenue This Year | $12.18 | N/A |
| Revenue Next Year | $8.44 | $534.24 |
| P/E Ratio | $2,631.75 | ★ N/A |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $71.02 | $27.07 |
| 52 Week High | $155.82 | $56.54 |
| Indicator | IPGP | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 66.95 |
| Support Level | $104.22 | $44.08 |
| Resistance Level | $126.78 | N/A |
| Average True Range (ATR) | 6.18 | 2.31 |
| MACD | -0.34 | 0.78 |
| Stochastic Oscillator | 26.24 | 86.67 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.